The disclosure provides a non-naturally occurring BAFF-R glycoprotein having adeletion in the extracellular domain which results in an altered 0-linkedglycosylation pattern. The disclosure also provides methods and pharmaceuticalcompositions for treating B-cell- and T-cell-mediated disorders.